

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT

MANDI® RANKED THE FIRST PLACE ON MULTIPLE PLATFORMS IN “DOUBLE 11” OF 2024

This announcement is made voluntarily by 3SBio Inc. (the “**Company**”).

During the “Double 11” campaign in 2024, Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (“**Sunshine Mandi**”), a subsidiary of the Company achieved the following performance:

The main brand Mandi® was ranked the first place in the OTC brand accumulative payment gross merchandise volume (“**GMV**”) list on Tmall Platforms; the core product Mandi® Minoxidil Foam was awarded the first place in the OTC single product list in terms of payment GMV on JD Pharmacy; the main brand Mandi® was awarded the first place in the pharmaceutical and healthcare brand list in terms of payment GMV on TikTok shop.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shanghai, the PRC
14 November 2024

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Ms. ZHANG Jiaoe as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi and Mr. NG, Joo Yeow Gerry as independent non-executive Directors.